Ernexa Therapeutics Inc.
ERNA
$1.47
-$0.02-1.34%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 488.00K | 535.00K | 582.00K | 598.00K | 162.00K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 488.00K | 535.00K | 582.00K | 598.00K | 162.00K |
| Cost of Revenue | -60.00K | 35.00K | 96.00K | 162.00K | 342.00K |
| Gross Profit | 548.00K | 500.00K | 486.00K | 436.00K | -180.00K |
| SG&A Expenses | 7.90M | 10.43M | 13.32M | 16.13M | 16.80M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 12.25M | 14.73M | 17.83M | 20.92M | 22.15M |
| Operating Income | -11.76M | -14.19M | -17.25M | -20.32M | -21.99M |
| Income Before Tax | -43.67M | -46.06M | -44.51M | -44.92M | -23.93M |
| Income Tax Expenses | 34.00K | 34.00K | 30.00K | 15.00K | -5.00K |
| Earnings from Continuing Operations | -43.70 | -46.09 | -44.54 | -44.93 | -23.92 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -43.70M | -46.09M | -44.54M | -44.93M | -23.92M |
| EBIT | -11.76M | -14.19M | -17.25M | -20.32M | -21.99M |
| EBITDA | -11.67M | -14.08M | -17.11M | -20.18M | -21.86M |
| EPS Basic | -78.93 | -93.66 | -109.79 | -124.60 | -66.34 |
| Normalized Basic EPS | -13.40 | -22.70 | -32.77 | -41.78 | -41.56 |
| EPS Diluted | -78.93 | -93.66 | -109.79 | -124.60 | -66.34 |
| Normalized Diluted EPS | -13.40 | -22.70 | -32.77 | -41.78 | -41.56 |
| Average Basic Shares Outstanding | 11.65M | 6.84M | 3.64M | 1.44M | 1.44M |
| Average Diluted Shares Outstanding | 11.65M | 6.84M | 3.64M | 1.44M | 1.44M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | 0.00% | -0.02% | -0.02% | -0.04% | -0.07% |